m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00544
 [1], [2], [3], [4]
RNA modification MIR200B MIR200B ADAR Methylation : modification sites Indirect Enhancement m6A modification FSCN1 FSCN1 IGF2BP1 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Fascin (FSCN1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target MicroRNA 200b (MIR200B) View Details
Crosstalk Relationship A-to-I  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary ADAR1 interacts with MicroRNA 200b (MIR200B), increasing it's A-to-I level and promoting its physical interaction with Fascin (FSCN1), which was regulated by IGF2BP1-mediated m6A modification.
In-vitro Model
 Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Ej138 Bladder carcinoma Homo sapiens CVCL_2443
CAL-62 Thyroid gland anaplastic carcinoma Homo sapiens CVCL_1112
TPC-1 Thyroid gland papillary carcinoma Homo sapiens CVCL_6298
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Fascin (FSCN1) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name NP-G2-044 Phase 1 [5]
Synonyms
1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91844684
TTD: D0C2NT
DrugBank: DB14995
References
Ref 1 Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 2 CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression. Mol Cancer. 2021 Apr 14;20(1):68. doi: 10.1186/s12943-021-01359-x.
Ref 3 ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. 2020 Apr;39(18):3738-3753. doi: 10.1038/s41388-020-1248-x. Epub 2020 Mar 10.
Ref 4 MiR-200b/c family inhibits renal fibrosis through modulating epithelial-to-mesenchymal transition via targeting fascin-1/CD44 axis. Life Sci. 2020 Jul 1;252:117589. doi: 10.1016/j.lfs.2020.117589. Epub 2020 Mar 24.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)